Article

Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: functional regulation of LDLR levels

2022-10-21

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Objective</h4> The liver-derived circulating PCSK9 enhances the degradation of the LDL receptor (LDLR) in endosomes/lysosomes. PCSK9 inhibition or silencing is presently used in clinics worldwide to reduce LDL-cholesterol, resulting in lower incidence of cardiovascular disease and possibly cancer/metastasis. The mechanism by which the PCSK9-LDLR complex is sorted to degradation compartments...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 21eec946-0378-5609-98df-257d420c75e6
DOI: 10.1101/2022.10.20.513093

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: functional regulation of LDLR levelsDOI 10.1101/2022.10.20.513093Read

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Semantic proximity Read

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read

[Progress on the molecular mechanisms of PCSK9-mediated degradation of low density lipoprotein receptor].Semantic proximity Read

Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed MutagenesisSemantic proximity Read

The ever-expanding saga of the proprotein convertases and their roles in body homeostasis: emphasis on novel proprotein convertase subtilisin kexin number 9 functions and regulationSemantic proximity Read

PCSK9 and LDL cholesterol: unravelling the target to design the bullet.Semantic proximity Read

[PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].Semantic proximity Read

Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).Semantic proximity Read

PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.Semantic proximity Read

New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol.Semantic proximity Read

Potent Efficacy of Computer-Aided Designed Peptide Degrader Drug on PCSK9-Mediated HypercholesterolemiaSemantic proximity Read

ANGPTL3 binds to PCSK9 to coordinately regulate intracellular lipid homeostasisSemantic proximity Read